spacer
home > ebr > summer 2018 > alternative approaches
PUBLICATIONS
European Biopharmaceutical Review

Alternative Approaches

Novel cancer therapies extend far beyond traditional chemo- and radiotherapy approaches. Specific small-molecule inhibitors or antibodies targeting epitopes at the surface of cancer cells are employed to fight cancer cells. Antibody-drug conjugates deliver toxic or radioactive compounds directly to the tumour cell, and bispecific antibodies present tumour cells to the immune system. Even more advanced immune therapies such as CAR-T techniques boost the immune system by modifying T-cells. Stem cell and gene editing-based therapies are getting off the starting blocks, raising hopes towards more effective and safer cancer therapies.

Despite their structural and molecular diversity, these novel therapies have one thing in common: unlike conventional therapies, which attack every fast-dividing cell, they aim to specifically target features unique to tumour cells, allowing the use of highly potent therapies while minimising side effects on healthy tissue. Therefore, identification and characterisation of target structures is a prerequisite to the success of novel cancer therapies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Ute Boronowsky is a freelance science and marketing writer, translator, and journalist, covering topics relevant to the biotech and pharma industry. She received a PhD in biochemistry from the University of Bochum, Germany, did post-doctoral research in biochemistry at UCLA, US, and holds a degree in science journalism from the mibeg Institute for Media in Cologne, Germany. Ute has more than 15 years working experience from sales and marketing positions in the biotech industry and is co-founder of the start-up company Cube Biotech. She is member of the Chartered Institute of Linguists, UK, and of the Science Inbound writer’s network.
spacer
Dr Ute Boronowsky
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 
Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement